secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0001193125-24-014835
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron Therapeutics discloses license agreements, cash position, and Series X terms
--------------------------------------------------------------------------------

- Reports $19.9M cash as of Nov 30, 2023; expects to fund operations into Q4 2024.
- Assumed five license agreements from Lung acquisition: Taiho, UTHSCT, UT Austin, MUSC, Vivarta.
- Series X Preferred Stock: 4,707 shares + warrants for 2,353,500 shares; raised $18.4M.
- If stockholder approval not obtained, holders can require cash settlement on conversion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524014835/0001193125-24-014835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524014835/d154367d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-014835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer